Related Experiment Videos
One day vs. two days of prophylactic antibiotics in patients undergoing major head and neck surgery
Abstract:
Thirty patients undergoing major head and neck surgery were prospectively randomized to receive moxalactam (30 mg/kg) before surgery and for either 3 or 6 doses total postoperatively. Wound infection criteria were carefully specified and serum drug levels were monitored. Overall infection rate was 3%; the single infection occurred in a patient randomized to the 3 dose protocol. There was no statistically significant difference in infection rates between the two groups. Drug serum levels between the groups did not differ and none of the patients developed significant drug side effects. We conclude that short course prophylaxis is equally effective as more prolonged therapy. Our wound infection rate compares favorably with previous studies and supports the use of moxalactam as a prophylactive antibiotic in major head and neck surgery.
Insights
Short-course moxalactam (an antibiotic) prophylaxis is effective for major head and neck surgery, showing similar infection rates to longer treatment durations. This study supports its use in preventing surgical site infections.
Area of Science:
- Surgical Oncology
- Infectious Diseases
- Pharmacology
Background:
- Major head and neck surgery carries a risk of surgical site infections.
- Antibiotic prophylaxis is standard practice to minimize infection risk.
- Optimizing the duration of antibiotic prophylaxis is crucial for efficacy and reducing resistance.
Purpose of the Study:
- To compare the efficacy of short-course (3 doses) versus prolonged-course (6 doses) moxalactam prophylaxis.
- To evaluate the incidence of wound infections in patients undergoing major head and neck surgery.
- To assess serum drug levels and side effects associated with moxalactam prophylaxis.
Main Methods:
- Prospective randomized trial involving 30 patients undergoing major head and neck surgery.
- Patients received moxalactam (30 mg/kg) preoperatively and either 3 or 6 doses postoperatively.
- Wound infection criteria were defined, and serum drug levels were monitored.
Main Results:
- An overall wound infection rate of 3% was observed.
- The single infection occurred in the 3-dose group; no statistically significant difference in infection rates between groups.
- Serum drug levels were comparable between the 3-dose and 6-dose groups.
- No significant drug-related side effects were reported.
Conclusions:
- Short-course moxalactam prophylaxis (3 doses) is as effective as prolonged therapy (6 doses) in preventing wound infections.
- Moxalactam demonstrates favorable safety and efficacy for prophylactic use in major head and neck surgery.
- The low infection rate supports the use of moxalactam for surgical prophylaxis.